Company News 

Oxford BioDynamics attracts the big guns of global pharma

Oxford BioDynamics attracts the big guns of global pharma

Announcements have gushed out of the press office of genetics specialist Oxford BioDynamics (OBD) in the last six months and investors have started to take notice. The shares hit a record high of 279p in October after the group’s proprietary biotechnology platform EpiSwitch was successful is diagnosing breast cancer, earned patent approval in the US, and began to generate commercial interest in Asia. Recently signed partnerships with two major US pharma companies have created optimism that OBD and EpiSwitch could play an important role in the future of personalised medicine.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now